
CLAIMS


1. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein

ring A is any of the following ring:



(a2) (b2)

X1 is $CR^{A9a}R^{A9b}$ or O;

R^{A5a}, R^{A5b}, R^{A6a}, R^{A6b}, R^{A7a} and R^{A7b} are each independently hydrogen, alkyl , alkyloxy, or alkyloxyalkyl;

R^{A5a} and R^{A6a}, or R^{A6a} and R^{A7a} may be taken together with the adjacent at oms to form an aromatic carbocycle optionally substituted by halogen, a 3- to 6-membered nonaromatic carbocycle optionally substituted by halogen, or a 4- to 6-membered nonaromatic heterocycle optionally substituted by halogen, provided tha t, when forming an aromatic carbocycle, R^{A5b} and R^{A6b}, or R^{A6b} and R^{A7b} are take n together to form a bond;

R^{A5b} and R^{A6b} may be taken together to form a bond;

R^{A8a}, R^{A8b}, R^{A9a}, R^{A9b}, R^{A10a}, R^{A10b}, R^{A11a} and R^{A11b} are each independently hydrogen, alkyl, alkyloxy, or alkyloxyalkyl;

R^{A8a} and R^{A10a} may be taken together to form a C1-C3 cross-link;

R^{A10a} and R^{A11a} may be taken together with the adjacent atoms to form a 5 -membered nonaromatic carbocycle;

R^{A9a} and R^{A9b} may be taken together with the adjacent atom to form a 4-m embered nonaromatic carbocycle or a 5-membered nonaromatic heterocycle;

R^{A8a} and R^{A9a} may be taken together to form a bond;

ring C is a benzene ring or a pyridine ring;

R^1 is each independently halogen, alkyl, haloalkyl, alkyloxy, cyano, or haloa lkyloxy;


R^{2a} and R^{2b} are each independently hydrogen, alkyl, or haloalkyl;

R^3 is alkyl or haloalkyl;


R^4 is hydrogen or alkyl;

n is an integer of 1 to 3, and


provided that the following compounds are excluded:




II-020



II-031




II-042




II-060


2. A compound or a pharmaceutically acceptable salt thereof, wherein the com pound is selected from the group consisting of




I-001




II-23




II-24




II-26




II-27




II-66




II-106




II-108




II-126




II-22




II-10




II-11




II-49




II-51




II-65




II-112



II-119




II-121




I-15


and





II-87


3. A compound or a pharmaceutically acceptable salt thereof, wherein the com pound is selected from the group consisting of



I-15



II-007



II-14



II-22


II-27



II-47


II-49


II-87



II-108

and


II-117


.

4. A compound or a pharmaceutically acceptable salt thereof, wherein the com pound is


I-15

.


5. A compound or a pharmaceutically acceptable salt thereof, wherein the com pound is



II-007

.


6. A compound or a pharmaceutically acceptable salt thereof, wherein the com pound is



II-14

.


7. A compound or a pharmaceutically acceptable salt thereof, wherein the com pound is



II-22

.


8. A compound or a pharmaceutically acceptable salt thereof, wherein the com pound is



II-27

.


9. A compound or a pharmaceutically acceptable salt thereof, wherein the com pound is



II-47

.


10. A compound or a pharmaceutically acceptable salt thereof, wherein the com pound is



II-49

.


11. A compound or a pharmaceutically acceptable salt thereof, wherein the com pound is



II-87

.


12. A compound or a pharmaceutically acceptable salt thereof, wherein the com pound is



II-108

.

13. A compound or a pharmaceutically acceptable salt thereof, wherein the com pound is



II-117

.

14. A pharmaceutical composition for treating and/or preventing HIV infection, co mprising the compound as claimed in any one of claims 1 to 13 or a pharm aceutically acceptable salt thereof.

15. Use of the compound according to any one of claims 1 to 13 or a pharmac eutically acceptable salt thereof in the manufacture of a medicament for treat ing and/or preventing HIV infection.